Given the unique binding characteristics, high binding affinity and functional pre-clinical activity of E2814, further clinical investigation is warranted to test whether the antibody can indeed prevent further aggregation of tau and slow transmission of pathology in AD and potentially other tauopathies. This evidence concerns the gene MAPT and tauopathy.